Number: 201310089 Principal Investigator: Aft, Rebecca
Title: Effect of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters
Phase: II Disease Site: Breast, Female
Participating Site(s):
Main Campus
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
Contact: 800-600-3606 or

The purpose of this study is to determine whether platinum-based chemotherapy (either cisplatin or carboplatin), when given with radiation therapy prior to surgery, is effective in improving response to
treatment in triple negative breast cancer patients. This treatment is being studied in this type of breast cancer because it does not respond well to commonly used treatments such as tamoxifen or herceptin.
If you enroll in this study, you will be treated with either cisplatin or carboplatin, both chemotherapy drugs. Cisplatin has been approved by the Food and Drug Administration (FDA) for the treatment of testicular, ovarian, and bladder cancers, but it is not FDA approved for the treatment of breast cancer
and is considered an investigational drug in this study. Carboplatin has been approved by the FDA for treatment of ovarian, lung, and head and neck cancers, but it is also not FDA approved for the treatment of breast cancer and is considered investigational as well.
More Information: Entry
Internal Protocol Documents (requires Siteman administrative database password)